Tambjamines as Fast-Acting Multistage Antimalarials.

Journal: ACS Infectious Diseases
Published:
Abstract

Well-tolerated and novel antimalarials that can combat multiple stages of the parasite life cycle are desirable but challenging to discover and develop. Herein, we report results for natural product-inspired novel tambjamine antimalarials. We show that they are potent against liver, asexual erythrocytic, and sexual erythrocytic parasite life cycle stages. Notably, our lead candidate 1 (KAR425) displays excellent oral efficacy with complete clearance of parasites within 72 h of treatment in the humanized Plasmodium falciparum (NOD-scid) mouse model at 50 mg/kg × 4 days. Profiling of compound 1 demonstrated a fast in vitro killing profile. In addition, several other tambjamine analogues cured erythrocytic Plasmodium yoelii infections after oral doses of 30 and 50 mg/kg × 4 days in a murine model while exhibiting good safety and metabolic profiles. This study presents the first account of multiple-stage antiplasmodial activities with rapid killing profile in the tambjamine family.

Authors
Amrendra Kumar, Yuexin Li, Rozalia Dodean, Alison Roth, Diana Caridha, Michael Madejczyk, Xiannu Jin, William Dennis, Patricia Lee, Brandon Pybus, Monica Martin, Kristina Pannone, Hieu Dinh, Cameron Blount, Ravi Chetree, Jesse Deluca, Martin Evans, Robert Nadeau, Chau Vuong, Susan Leed, Chad Black, Jason Sousa, Christina Nolan, Frida Ceja, Stephanie Rasmussen, Patrick Tumwebaze, Philip Rosenthal, Roland Cooper, Matthias Rottmann, Pamela Orjuela Sanchez, Stephan Meister, Elizabeth Winzeler, Michael Delves, Holly Matthews, Jake Baum, Robert Kirby, Jeremy Burrows, James Duffy, David Peyton, Kevin Reynolds, Jane Kelly, Papireddy Kancharla
Relevant Conditions

Malaria